A citation-based method for searching scientific literature

Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, Silvia Peiti, Simonetta Genovesi. Drugs 2021
Times Cited: 6







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
786
33

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. J Am Soc Nephrol 2021
15
33

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Claes Held, Fan-Fan Hou,[...]. Circulation 2021
29
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
George Bakris, Megumi Oshima, Kenneth W Mahaffey, Rajiv Agarwal, Christopher P Cannon, George Capuano, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene,[...]. Clin J Am Soc Nephrol 2020
28
33

[ST-elevation myocardial infarction (STEMI) in the elderly].
Z Terzian, M Slama. Ann Cardiol Angeiol (Paris) 2018
2
50

[Update ESC Guideline 2017 - Acute Myocardial Infarction (STEMI)].
Christian Jung, Albrecht Elsässer. Dtsch Med Wochenschr 2018
4
25

Evolution of STEMI network in Italy.
Leonardo De Luca, Francesco Saia. Minerva Cardioangiol 2018
2
50

Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, Ofri Mosenzon, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, Erica L Goodrich, Remo Holanda De Mendonca Furtado, John P H Wilding,[...]. Circulation 2020
14
16

[COVID-19 and STEMI].
R Hakim, P Motreff, G Rangé. Ann Cardiol Angeiol (Paris) 2020
1
100

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, Mirta Diez, Mark C Petrie, Subodh Verma, Jose C Nicolau, Béla Merkely, Masafumi Kitakaze, David L DeMets,[...]. Circulation 2020
118
16


The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
451
16

Adiponectin in onset and progression of T2DM with cardiac dysfunction in rats.
C Gupta, P Bubber, M Fahim, B Saidullah, S Omanwar. Hum Exp Toxicol 2020
4
25



Management of STEMI during the COVID-19 pandemic: Lessons learned in 2020 to prepare for 2021.
Vardhmaan Jain, Kartik Gupta, Kirtipal Bhatia, Agam Bansal, Sameer Arora, Akshay K Khandelwal, Jonathan R Rosenberg, Justin P Levisay, Carl L Tommaso, Mark J Ricciardi,[...]. Trends Cardiovasc Med 2021
7
16


Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
88
16

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
David Z I Cherney, Claire C J Dekkers, Sean J Barbour, Daniel Cattran, Abdul Halim Abdul Gafor, Peter J Greasley, Gozewijn D Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N Reich,[...]. Lancet Diabetes Endocrinol 2020
66
16

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2019
26
16

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
127
16

Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review.
Thomas R Einarson, Annabel Acs, Craig Ludwig, Ulrik H Panton. Value Health 2018
84
16

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
16

Recent progress in genetic and epigenetic research on type 2 diabetes.
Soo Heon Kwak, Kyong Soo Park. Exp Mol Med 2016
84
16

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
M Arow, M Waldman, D Yadin, V Nudelman, A Shainberg, N G Abraham, D Freimark, R Kornowski, D Aravot, E Hochhauser,[...]. Cardiovasc Diabetol 2020
48
16

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
16

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease.
Swetha R Kanduri, Karthik Kovvuru, Panupong Hansrivijit, Charat Thongprayoon, Saraschandra Vallabhajosyula, Aleksandra I Pivovarova, Api Chewcharat, Vishnu Garla, Juan Medaura, Wisit Cheungpasitporn. J Clin Med 2020
8
16

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan,[...]. J Clin Epidemiol 2021
152
16

Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.
Feby Savira, Ruth Magaye, Danny Liew, Christopher Reid, Darren J Kelly, Andrew R Kompa, S Jeson Sangaralingham, John C Burnett, David Kaye, Bing H Wang. Br J Pharmacol 2020
22
16

Quantifying heterogeneity in a meta-analysis.
Julian P T Higgins, Simon G Thompson. Stat Med 2002
16

Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.
Miranda Cumpston, Tianjing Li, Matthew J Page, Jacqueline Chandler, Vivian A Welch, Julian Pt Higgins, James Thomas. Cochrane Database Syst Rev 2019
16



Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
266
16

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
16

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
294
16

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Michael Joubert, Benoît Jagu, David Montaigne, Xavier Marechal, Angela Tesse, Audrey Ayer, Lucile Dollet, Cédric Le May, Gilles Toumaniantz, Alain Manrique,[...]. Diabetes 2017
81
16

Cardiorenal Syndrome: An Overview.
Claudio Ronco, Antonio Bellasi, Luca Di Lullo. Adv Chronic Kidney Dis 2018
45
16

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
14
16

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
373
16


Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Diabetes Obes Metab 2021
1
100

Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Laween Uthman, Marius Kuschma, Gregor Römer, Marleen Boomsma, Jens Kessler, Jeroen Hermanides, Markus W Hollmann, Benedikt Preckel, Coert J Zuurbier, Nina C Weber. Cardiovasc Drugs Ther 2021
13
16

Kidney Function and Outcomes in Patients Hospitalized With Heart Failure.
Ravi B Patel, Gregg C Fonarow, Stephen J Greene, Shuaiqi Zhang, Brooke Alhanti, Adam D DeVore, Javed Butler, Paul A Heidenreich, Joanna C Huang, Michelle M Kittleson,[...]. J Am Coll Cardiol 2021
16
16

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Vjera Ninčević, Tea Omanović Kolarić, Hrvoje Roguljić, Tomislav Kizivat, Martina Smolić, Ines Bilić Ćurčić. Int J Mol Sci 2019
28
16


Association between normal or mildly reduced kidney function, cardiovascular risk and biomarkers for atherosclerosis: results from the ENCORE trial.
Crystal C Tyson, Patrick J Smith, Andrew Sherwood, Stephanie Mabe, Alan L Hinderliter, James A Blumenthal. Clin Kidney J 2017
5
20

The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
86
16

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Rev Esp Cardiol (Engl Ed) 2017
46
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.